Fundraising Overview - The company has been approved by the China Securities Regulatory Commission to issue no more than 64,299,200 new shares, of which 31,420,573 shares were actually issued at a price confirmed on September 5, 2022 [1] - The funds raised are managed in accordance with regulatory guidelines and the company's internal management system, with specific accounts opened at various banks for the purpose of fund storage and management [1][2] Fund Usage and Account Status - The company has established special accounts for the raised funds at several banks, including China Construction Bank and Minsheng Bank, for projects such as the production of inactivated vaccines and the expansion of biological product workshops [2] - As of the announcement date, the status of the fundraising accounts is active, with specific projects linked to each account [2] Project Completion and Fund Reallocation - The company has concluded certain fundraising projects, specifically the "inactivated vaccine production project" and the "product quality inspection workshop project," and has decided to permanently allocate the remaining funds to working capital [3] - Following the completion of these projects, the corresponding fundraising accounts will be closed, and the related storage agreements will be terminated [3]